MeCure Industries Plc is making waves with the launch of its ₦10 billion Series 6 Commercial Paper (CP), a key part of its ₦40 billion CP programme.
Offering a discount rate of 18.19% and an effective annual yield of 21%, the CP has attracted attention from investors seeking strong short-term returns.
Strong Financial Performance
The company opens subscriptions on December 9, 2025, closing them on December 12, 2025.
Investors must commit a minimum of ₦5 million, adding in multiples of ₦1,000.
The company will settle payments on December 14, 2025, and investors will receive full returns when the CP matures on September 26, 2026.
Read Also: Nigeria’s FX Inflows Plunge To $2B, 16-Month Low
MeCure’s recent performance reinforces confidence in the issuance.
For the nine months ending September 30, 2025, the company grew revenue by 98.6% year-on-year, reaching ₦60.01 billion, compared with ₦30.22 billion in 2024.
Furthermore, operating profit soared 159%, hitting ₦13.02 billion, up from ₦5.03 billion.
MeCure Strategic Growth And Support
Strong operational management keeps MeCure’s interest coverage ratio at 1.96x, demonstrating its ability to meet obligations.
Although commercial paper now forms 53% of total debt, the company manages it comfortably.
After the Series 6 CP issuance, the ratio will likely drop to 1.49x, yet provides a safe margin for payments.
Government duty waivers boost MeCure’s competitiveness, while its Beta-Lactam plant, producing Amoxicillin-Clavulanic acid, targets a ₦500 billion market.
With consistent growth, rising profits, and supportive policies, MeCure positions the Series 6 CP as a compelling short-term investment opportunity, promising both returns and security.
